<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03565666</url>
  </required_header>
  <id_info>
    <org_study_id>2018P000853</org_study_id>
    <nct_id>NCT03565666</nct_id>
  </id_info>
  <brief_title>The Insulin-Only Bionic Pancreas Bridging Study</brief_title>
  <official_title>The Insulin-Only Bionic Pancreas Bridging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The iLet is a closed-loop delivery system that can be used in insulin-only, bihormonal, or
      glucagon-only configurations. Previous studies have utilized a phone-based bionic pancreas.
      The iLet consists of a touchscreen-enabled, menu-driven user interface and an onboard
      microprocessor that provides a comprehensive and standalone platform, which allows the iLet
      to operate independently of smartphones or other devices and without the need for internet
      support during routine operation.

      This is a multicenter study of adult participants with type 1 diabetes, who will manage their
      diabetes with the iLet bionic pancreas compared to usual care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will serve as a transitional study, bridging to larger and longer outpatient
      pivotal studies using the insulin-only configuration of the bionic pancreas.

      The Adult RCT Period will consist of a multi-center, three-period, random-order, cross-over,
      feasibility study in 36 adult participants ≥ 18 years old with T1D. Insulin therapy for each
      participant will be administered (i) using the iLet in the insulin-only configuration and the
      insulin analog that they use for their usual care (either Humalog or Novolog) for 7 days,
      (ii) in another period using the iLet in the insulin-only configuration with faster insulin
      aspart (Fiasp) for 7 days (iii) in a third period using the participant's own usual care (UC)
      for 7 days. All three experimental periods will be followed by round-the-clock, remote,
      telemetric monitoring for hyperglycemia (&gt; 300 mg/dl for ≥ 90 minutes) and hypoglycemia (&lt; 50
      mg/dl for ≥ 15 minutes). Half the subjects enrolled were expected to manage their diabetes
      with MDI and the other half with insulin pumps in their UC. An implantable Eversense CGM will
      also be placed in half the study participants for a CGM comparison.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Actual">November 19, 2018</completion_date>
  <primary_completion_date type="Actual">November 19, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean CGM Glucose</measure>
    <time_frame>Days 3-7 for the RCT Period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Time Where Glucose is Less Than 54 mg/dL</measure>
    <time_frame>Days 3-7 for the RCT Period</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Episodes of Severe Hypoglycemia</measure>
    <time_frame>Days 3-7 for the RCT Period</time_frame>
    <description>Pre-specified to report the total number of episodes summed across all participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Episodes of Diabetic Ketoacidosis (DKA)</measure>
    <time_frame>Days 3-7 for the RCT Period</time_frame>
    <description>pre-specified to report the total number of episodes summed across all participants</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Time Where Glucose is Less Than 70 mg/dL</measure>
    <time_frame>Days 3-7 for the RCT Period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Time in the Glucose Target Range of 70-180 mg/dl</measure>
    <time_frame>Days 3-7 for the RCT Period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Time Where Glucose is Greater Than 180 mg/dL</measure>
    <time_frame>Days 3-7 for the RCT Period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Time Where Glucose is Less Than 60 mg/dL</measure>
    <time_frame>Days 3-7 for the RCT Period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Time Where Glucose is Greater Than 250 mg/dL</measure>
    <time_frame>Days 3-7 for the RCT Period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage Time in the Glucose Target Range of 70-120mg/dL</measure>
    <time_frame>Days 3-7 for the RCT Period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Absolute Relative Difference Between Dexcom G5 CGM and Contour Next One Glucose Meter</measure>
    <time_frame>Days 3-7 for the RCT Period</time_frame>
    <description>The MARD is calculated as the mean value of individual absolute relative differences (ARD). The ARD is calculated as follows: 100*(CGM-reference glucose)/reference glucose</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Absolute Relative Difference Between Senseonics Eversense CGM and Contour Next One Glucose Meter</measure>
    <time_frame>Days 1-7 of the Adult RCT period</time_frame>
    <description>The MARD is calculated as the mean value of individual absolute relative differences (ARD). The ARD is calculated as follows: 100*(CGM-reference glucose)/reference glucose</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Type1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Adult RCT: Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to usual care first started the usual care arm (UC) managing their diabetes with either multiple daily injections or continuous subcutaneous insulin infusion (pump therapy) for 7 days. All subjects wore a Dexcom G5 continuous glucose monitor (CGM) and half of all subjects also were a senseonics CGM. The usual care period was followed by the other 2 arms according to each subject's randomization schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult RCT: closed-loop control with iLet Humalog or Novolog</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the iLet with humalog/novolog first started the insulin-only iLet arm using the insulin analog that they use for their usual care (either Humalog or Novolog). All subjects wore a Dexcom G5 CGM and half of all subjects also wore a Senseonics Eversense CGM. The iLet period was followed by the other 2 arms according to each subject's randomization schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult RCT: closed-loop control with iLet using Fiasp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the iLet with Fiasp first started the insulin-only iLet arm using faster insulin aspart (Fiasp) in PumpCart, where the pharmacokinetic (PK) parameter for tmax used by the insulin-dosing algorithm was set to the same value as is used for Humalog and Novolog (65 minutes). All subjects wore a Dexcom G5 CGM and half of all subjects also wore a Senseonics Eversense CGM. The iLet period was followed by the other 2 arms according to each subject's randomization schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog</intervention_name>
    <description>iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog</description>
    <arm_group_label>Adult RCT: closed-loop control with iLet Humalog or Novolog</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iLet Bionic Pancreas insulin-only configuration with Fiasp</intervention_name>
    <description>iLet Bionic Pancreas insulin-only configuration with Fiasp (faster insulin aspart)</description>
    <arm_group_label>Adult RCT: closed-loop control with iLet using Fiasp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Usual care</description>
    <arm_group_label>Adult RCT: Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis of type 1 diabetes for at least one year and using insulin for at
             least 1 year

          2. Diabetes managed using an insulin pump for ≥ 3 months or with multiple daily
             injections (approximately 1/2 of participants should use a pump and approximately 1/2
             should use MDI)

          3. Age ≥18 years;

             • There is no upper age limit in the Adult RCT Period (instead the exclusion criteria
             are used to restrict the participants to those healthy enough to participate in the
             trial)

          4. HbA1c level &lt;11.0%

             • A point of care or local lab measurement is used to assess eligibility for
             screening.

          5. At least 3 SMBG meter tests daily on average or use of a CGM and 2 or more SMBG meter
             tests daily on average by history

          6. For females, not currently known to be pregnant

             • If female, sexually active, and at risk for pregnancy, must agree to use a highly
             effective form of contraception to prevent pregnancy while a participant in the study.
             A negative urine pregnancy test will be required for all women who are post-menarche
             and pre-menopause who are not surgically sterile. Participants who become pregnant
             will be discontinued from the study.

          7. An understanding of and willingness to follow the protocol and sign the informed
             consent and assent where applicable

        Exclusion Criteria:

        -The presence of any of the following is an exclusion for the study:

          1. Unable to provide informed consent (e.g. impaired cognition or judgment)

          2. Unable to safely comply with study procedures and reporting requirements (e.g.
             impairment of vision or dexterity that prevents safe operation of the BP, impaired
             memory)

          3. Unable to speak and read English

          4. Currently using for the first time a real-time CGM for &lt; 1 month (Individuals who have
             been using CGM for 1 or more months are eligible)

          5. Current use of non-FDA approved closed-loop or hybrid closed-loop insulin delivery
             system

          6. Current use of insulin glulisine (Apidra) as part of usual diabetes home regimen

          7. Current off-label use of faster-acting insulin aspart (Fiasp) in CSII therapy as part
             of usual diabetes home regimen

          8. Current participation in another diabetes-related clinical trial that, in the judgment
             of the principal investigator, will compromise the results of this study or the safety
             of the participant

          9. Pregnant (positive urine HCG), breast feeding, plan to become pregnant in the next 12
             months, or sexually active and at risk for pregnancy without use of contraception

         10. Current alcohol abuse (intake averaging &gt;4 drinks daily in last 30 days) or other
             substance abuse (use within the last 3 months of controlled substances other than
             marijuana without a prescription)

         11. Unwilling or unable or to avoid use of drugs that may dull the sensorium, reduce
             sensitivity to symptoms of hypoglycemia, or hinder decision making during the period
             of participation in the study (use of benzodiazepines or narcotics, even if by
             prescription, may be excluded according to the judgment of the principal investigator)

         12. Stage 4 renal failure (eGFR &lt;30) or Stage 5 renal failure on dialysis (hemodialysis or
             peritoneal dialysis)

         13. History of cystic fibrosis, pancreatitis, or other pancreatic disease, including
             pancreatic tumor or insulinoma, or history of complete pancreatectomy

         14. Coronary artery disease that is not stable with medical management, including unstable
             angina, angina that prevents moderate exercise (e.g. exercise of intensity up to 6
             METS) despite medical management, or within the last 12 months before screening a
             history of myocardial infarction, percutaneous coronary intervention, enzymatic lysis
             of a presumed coronary occlusion, or coronary artery bypass grafting

         15. Abnormal EKG consistent with increased risk of malignant arrhythmia including, but not
             limited to, evidence of active ischemia, proximal LAD critical stenosis (Wellen's
             sign), or prolonged QT interval (&gt; 440 ms). Other EKG findings, including stable Q
             waves, are not grounds for exclusion as long as the participant is not excluded
             according to other criteria. A reassuring evaluation by a cardiologist after an
             abnormal EKG finding may allow participation.

             • EKG is only required for participants ≥50 years old or with diabetes duration ≥20
             years

         16. For participants &lt; 50 years of age and &lt; 20 years since diagnosis: History of
             prolonged QT interval, malignant arrhythmia, or congenital heart disease

         17. Congestive heart failure with New York Heart Association (NYHA) Functional
             Classification III or IV

         18. History of TIA or stroke in the last 12 months

         19. Recent history of diabetic ketoacidosis (DKA) or severe hypoglycemia in the last 6
             months. Severe hypoglycemia is defined as an event that required assistance of another
             person due to altered consciousness, and required another person to actively
             administer carbohydrate, glucagon, or other resuscitative actions. This means that the
             participant was impaired cognitively to the point that he/she was unable to treat
             himself/herself, was unable to verbalize his/ her needs, was incoherent, disoriented,
             and/or combative, or experienced seizure or coma.

         20. History of more than 1 episode of DKA requiring hospitalization in the last 2 years

         21. History of more than 1 episode of severe hypoglycemia in the last year.

         22. Untreated or inadequately treated mental illness (indicators would include symptoms
             such as psychosis, hallucinations, mania, and any psychiatric hospitalization in the
             last year), or treatment with anti-psychotic medications that are known to affect
             glucose regulation.

         23. Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be
             susceptible to RF interference

         24. Unable or unwilling to completely avoid acetaminophen for duration of study

         25. Established history of allergy or severe reaction to adhesive or tape that must be
             used in the study

         26. History of eating disorder within the last 2 years, such as anorexia, bulimia, or
             diabulemia or omission of insulin to manipulate weight

         27. Current or planned use of SGLT2 inhibitors (prior use more than 3 months prior to
             enrollment is acceptable; SGLT2 inhibitors should not be initiated during the trial)

         28. If using GLP1, pramlintide, or metformin must be on a stable dose for 3 months prior
             to enrollment (these agents should not be initiated during the trial)

         29. Required use of 2 or more steroid bursts in the 6 months prior to the trial

         30. History of intentional, inappropriate administration of insulin leading to severe
             hypoglycemia requiring treatment

         31. Any factors that, in the opinion of the site principal investigator or clinical
             protocol chair, would interfere with the safe completion of the study, including
             medical conditions that may require hospitalization during the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Childhood Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Specialty Care</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 29, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <results_first_submitted>April 15, 2019</results_first_submitted>
  <results_first_submitted_qc>September 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2019</results_first_posted>
  <last_update_submitted>September 2, 2019</last_update_submitted>
  <last_update_submitted_qc>September 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven J. Russell, MD, PhD</investigator_full_name>
    <investigator_title>Clinical Study Director</investigator_title>
  </responsible_party>
  <keyword>bionic pancreas</keyword>
  <keyword>closed loop</keyword>
  <keyword>insulin</keyword>
  <keyword>continuous glucose monitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified IPD will be published as online supplemental material to the main paper describing the results, as we have done for all of our previous bionic pancreas studies.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT03565666/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT03565666/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>18 participants were recruited at MGH and 18 participants at Stanford</recruitment_details>
      <pre_assignment_details>This study consisted of a test-run period followed by an RCT</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Usual Care Then Either iLet/Novolog/Humalog or iLet/Fiasp</title>
          <description>Participants first started the usual care arm (managing their diabetes with either multiple daily injections or insulin pump) for 7 days, then switched to either the insulin-only iLet using Novolog or Humalog for 7 days, or the insulin-only iLet using Fiasp for 7 days. No washout period was required between arms</description>
        </group>
        <group group_id="P2">
          <title>iLet/Novolog/Humalog Then Either iLet/Fiasp or Usual Care</title>
          <description>Participants first started using the insulin-only iLet with either Novolog or Humalog for 7 days then switched to either the usual care arm (managing their diabetes with multiple daily injections or insulin pump) for 7 days, or the insulin-only iLet arm using Fiasp for 7 days. No washout period was required between arms.</description>
        </group>
        <group group_id="P3">
          <title>iLet/Fiasp Then Either iLet With Novolog/Humalog or Usual Care</title>
          <description>Participants first started the insulin-only iLet using Fiasp for 7 days, then switched to either the insulin-only iLet arm using Novolog or Humalog for 7 days or the usual care arm, (managing their diabetes with either multiple daily injections or insulin pump) for 7 days. No washout period was required between arms</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>36 adult patients with type 1 diabetes will complete 3 arms in a random-order crossover fashion. Participants in the usual care arm (UC) will manage their diabetes with either multiple daily injections or continuous subcutaneous insulin infusion (pump therapy). All subjects will wear Dexcom G5 continuous glucose monitor (CGM) and half of all subjects will also wear a senseonics CGM.
Each arm is 7 days, no washout between arms</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>1 participant was not analysed as they discontinued the study after 1 day and did not meet the criteria for their results to be included in the analyses (according to the protocol)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White non-hispanic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bklack/African-American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian/Alaskan Native</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>1 participant was not analysed as they discontinued the study after 1 day and did not meet the criteria for their results to be included in the analyses (according to the protocol)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean CGM Glucose</title>
        <time_frame>Days 3-7 for the RCT Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care Arm</title>
            <description>Participants who completed 7 days of managing their diabetes with their usual care (either MDI or insulin pump) during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
          <group group_id="O2">
            <title>iLet With Insulin Analogue (Novolog/Humalog) Arm</title>
            <description>Participants who completed 7 days of using the iLet with either Novolog or Humalog to manage their diabetes during the 3 weeks of the study period 34 participants completed this arm</description>
          </group>
          <group group_id="O3">
            <title>iLet Using Fiasp Arm</title>
            <description>Participants who completed 7 days of using the iLet with faster acting aspart (Fiasp) to manage their diabetes during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
        </group_list>
        <measure>
          <title>Mean CGM Glucose</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.3" spread="9.5"/>
                    <measurement group_id="O2" value="162" spread="26"/>
                    <measurement group_id="O3" value="155" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Time Where Glucose is Less Than 54 mg/dL</title>
        <time_frame>Days 3-7 for the RCT Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care Arm</title>
            <description>Participants who completed 7 days of managing their diabetes with their usual care (either MDI or insulin pump) during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
          <group group_id="O2">
            <title>iLet With Insulin Analogue (Novolog/Humalog) Arm</title>
            <description>Participants who completed 7 days of using the iLet with either Novolog or Humalog to manage their diabetes during the 3 weeks of the study period 34 participants completed this arm</description>
          </group>
          <group group_id="O3">
            <title>iLet Using Fiasp Arm</title>
            <description>Participants who completed 7 days of using the iLet with faster acting aspart (Fiasp) to manage their diabetes during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Where Glucose is Less Than 54 mg/dL</title>
          <units>percentage of time</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" lower_limit="0.39" upper_limit="0.93"/>
                    <measurement group_id="O2" value="0.53" lower_limit="0.18" upper_limit="0.98"/>
                    <measurement group_id="O3" value="0.56" lower_limit="0.17" upper_limit="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Episodes of Severe Hypoglycemia</title>
        <description>Pre-specified to report the total number of episodes summed across all participants</description>
        <time_frame>Days 3-7 for the RCT Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care Arm</title>
            <description>Participants who completed 7 days of managing their diabetes with their usual care (either MDI or insulin pump) during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
          <group group_id="O2">
            <title>iLet With Insulin Analogue (Novolog/Humalog) Arm</title>
            <description>Participants who completed 7 days of using the iLet with either Novolog or Humalog to manage their diabetes during the 3 weeks of the study period 34 participants completed this arm</description>
          </group>
          <group group_id="O3">
            <title>iLet Using Fiasp Arm</title>
            <description>Participants who completed 7 days of using the iLet with faster acting aspart (Fiasp) to manage their diabetes during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
        </group_list>
        <measure>
          <title>Episodes of Severe Hypoglycemia</title>
          <description>Pre-specified to report the total number of episodes summed across all participants</description>
          <units>number of episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Episodes of Diabetic Ketoacidosis (DKA)</title>
        <description>pre-specified to report the total number of episodes summed across all participants</description>
        <time_frame>Days 3-7 for the RCT Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care Arm</title>
            <description>Participants who completed 7 days of managing their diabetes with their usual care (either MDI or insulin pump) during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
          <group group_id="O2">
            <title>iLet With Insulin Analogue (Novolog/Humalog) Arm</title>
            <description>Participants who completed 7 days of using the iLet with either Novolog or Humalog to manage their diabetes during the 3 weeks of the study period 34 participants completed this arm</description>
          </group>
          <group group_id="O3">
            <title>iLet Using Fiasp Arm</title>
            <description>Participants who completed 7 days of using the iLet with faster acting aspart (Fiasp) to manage their diabetes during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
        </group_list>
        <measure>
          <title>Episodes of Diabetic Ketoacidosis (DKA)</title>
          <description>pre-specified to report the total number of episodes summed across all participants</description>
          <units>number of episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Time Where Glucose is Less Than 70 mg/dL</title>
        <time_frame>Days 3-7 for the RCT Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care Arm</title>
            <description>Participants who completed 7 days of managing their diabetes with their usual care (either MDI or insulin pump) during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
          <group group_id="O2">
            <title>iLet Using Humalog/Novolog Arm</title>
            <description>Participants who completed 7 days of using the iLet with either Novolog or Humalog to manage their diabetes during the 3 weeks of the study period 34 participants completed this arm</description>
          </group>
          <group group_id="O3">
            <title>iLet Using Fiasp Arm</title>
            <description>Participants who completed 7 days of using the iLet with faster acting aspart (Fiasp) to manage their diabetes during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Where Glucose is Less Than 70 mg/dL</title>
          <units>percentage of time</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.09" lower_limit="3.73" upper_limit="5.5"/>
                    <measurement group_id="O2" value="3.2" lower_limit="1.3" upper_limit="5.2"/>
                    <measurement group_id="O3" value="2.7" lower_limit="1.5" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Time in the Glucose Target Range of 70-180 mg/dl</title>
        <time_frame>Days 3-7 for the RCT Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care Arm</title>
            <description>Participants who completed 7 days of managing their diabetes with their usual care (either MDI or insulin pump) during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
          <group group_id="O2">
            <title>iLet Using Humalog/Novolog Arm</title>
            <description>Participants who completed 7 days of using the iLet with either Novolog or Humalog to manage their diabetes during the 3 weeks of the study period 34 participants completed this arm</description>
          </group>
          <group group_id="O3">
            <title>iLet Using Fiasp Arm</title>
            <description>Participants who completed 7 days of using the iLet with faster acting aspart (Fiasp) to manage their diabetes during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time in the Glucose Target Range of 70-180 mg/dl</title>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3" spread="7.35"/>
                    <measurement group_id="O2" value="62.2" spread="16.2"/>
                    <measurement group_id="O3" value="69.2" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Time Where Glucose is Greater Than 180 mg/dL</title>
        <time_frame>Days 3-7 for the RCT Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care Arm</title>
            <description>Participants who completed 7 days of managing their diabetes with their usual care (either MDI or insulin pump) during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
          <group group_id="O2">
            <title>iLet Using Humalog/Novolog Arm</title>
            <description>Participants who completed 7 days of using the iLet with either Novolog or Humalog to manage their diabetes during the 3 weeks of the study period 34 participants completed this arm</description>
          </group>
          <group group_id="O3">
            <title>iLet Using Fiasp Arm</title>
            <description>Participants who completed 7 days of using the iLet with faster acting aspart (Fiasp) to manage their diabetes during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Where Glucose is Greater Than 180 mg/dL</title>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" spread="7.6"/>
                    <measurement group_id="O2" value="34.4" spread="16.9"/>
                    <measurement group_id="O3" value="27.96" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Time Where Glucose is Less Than 60 mg/dL</title>
        <time_frame>Days 3-7 for the RCT Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care Arm</title>
            <description>Participants who completed 7 days of managing their diabetes with their usual care (either MDI or insulin pump) during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
          <group group_id="O2">
            <title>iLet Using Humalog/Novolog Arm</title>
            <description>Participants who completed 7 days of using the iLet with either Novolog or Humalog to manage their diabetes during the 3 weeks of the study period 34 participants completed this arm</description>
          </group>
          <group group_id="O3">
            <title>iLet Using Fiasp Arm</title>
            <description>Participants who completed 7 days of using the iLet with faster acting aspart (Fiasp) to manage their diabetes during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Where Glucose is Less Than 60 mg/dL</title>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.73"/>
                    <measurement group_id="O2" value="1.3" spread="1.23"/>
                    <measurement group_id="O3" value="1.19" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Time Where Glucose is Greater Than 250 mg/dL</title>
        <time_frame>Days 3-7 for the RCT Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care Arm</title>
            <description>Participants who completed 7 days of managing their diabetes with their usual care (either MDI or insulin pump) during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
          <group group_id="O2">
            <title>iLet Using Humalog/Novolog Arm</title>
            <description>Participants who completed 7 days of using the iLet with either Novolog or Humalog to manage their diabetes during the 3 weeks of the study period 34 participants completed this arm</description>
          </group>
          <group group_id="O3">
            <title>iLet Using Fiasp Arm</title>
            <description>Participants who completed 7 days of using the iLet with faster acting aspart (Fiasp) to manage their diabetes during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Where Glucose is Greater Than 250 mg/dL</title>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" spread="3.03"/>
                    <measurement group_id="O2" value="10.42" spread="10.43"/>
                    <measurement group_id="O3" value="7.73" spread="4.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage Time in the Glucose Target Range of 70-120mg/dL</title>
        <time_frame>Days 3-7 for the RCT Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care Arm</title>
            <description>Participants who completed 7 days of managing their diabetes with their usual care (either MDI or insulin pump) during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
          <group group_id="O2">
            <title>iLet Using Humalog/Novolog Arm</title>
            <description>Participants who completed 7 days of using the iLet with either Novolog or Humalog to manage their diabetes during the 3 weeks of the study period 34 participants completed this arm</description>
          </group>
          <group group_id="O3">
            <title>iLet Using Fiasp Arm</title>
            <description>Participants who completed 7 days of using the iLet with faster acting aspart (Fiasp) to manage their diabetes during the 3 weeks of the study period 35 participants completed this arm</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Time in the Glucose Target Range of 70-120mg/dL</title>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.65" spread="4.17"/>
                    <measurement group_id="O2" value="25.65" spread="12.36"/>
                    <measurement group_id="O3" value="28.24" spread="7.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Absolute Relative Difference Between Dexcom G5 CGM and Contour Next One Glucose Meter</title>
        <description>The MARD is calculated as the mean value of individual absolute relative differences (ARD). The ARD is calculated as follows: 100*(CGM-reference glucose)/reference glucose</description>
        <time_frame>Days 3-7 for the RCT Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RCT Period Days 1-7</title>
            <description>36 adult patients with type 1 diabetes will complete 3 arms in a random-order crossover fashion. Half of the subjects (n=18) will wear the Dexcom G5 continuous glucose monitor (CGM) and the other half will wear a Senseonics Eversense CGM.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Relative Difference Between Dexcom G5 CGM and Contour Next One Glucose Meter</title>
          <description>The MARD is calculated as the mean value of individual absolute relative differences (ARD). The ARD is calculated as follows: 100*(CGM-reference glucose)/reference glucose</description>
          <units>MARD (CGMG-meter glucose)/meter glucose)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Absolute Relative Difference Between Senseonics Eversense CGM and Contour Next One Glucose Meter</title>
        <description>The MARD is calculated as the mean value of individual absolute relative differences (ARD). The ARD is calculated as follows: 100*(CGM-reference glucose)/reference glucose</description>
        <time_frame>Days 1-7 of the Adult RCT period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Days 1-7 of RCT</title>
            <description>36 adult patients with type 1 diabetes will complete 3 arms in a random-order crossover fashion. Half of the subjects (n=18) will wear the Dexcom G5 continuous glucose monitor (CGM) and the other half will wear a Senseonics Eversense CGM.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Relative Difference Between Senseonics Eversense CGM and Contour Next One Glucose Meter</title>
          <description>The MARD is calculated as the mean value of individual absolute relative differences (ARD). The ARD is calculated as follows: 100*(CGM-reference glucose)/reference glucose</description>
          <units>MARD: Mean of all [(CGMG − PG)/PG]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 2 months for the RCT</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Usual Care Arm</title>
          <description>Participants who completed 7 days of managing their diabetes with their usual care (either MDI or insulin pump) during the 3 weeks of the study period 35 participants completed this arm
Usual care: Usual care</description>
        </group>
        <group group_id="E2">
          <title>iLet With Humalog/Novolog Arm</title>
          <description>Participants who completed 7 days of using the iLet with either Novolog or Humalog to manage their diabetes during the 3 weeks of the study period 34 participants completed this arm</description>
        </group>
        <group group_id="E3">
          <title>iLet Using Fiasp Arm</title>
          <description>Participants who completed 7 days of using the iLet with faster acting aspart (Fiasp) to manage their diabetes during the 3 weeks of the study period 35 participants completed this arm</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Serious adverse event</sub_title>
                <description>Severe hypoglycemia defined as hypoglycemia necessitating the aid of a third party for recovery</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Non-serious adverse event</sub_title>
                <description>Elevated ketones &gt;1.0 mmol/L (no DKA)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Non-serious adverse event</sub_title>
                <description>Hypoglycemia For the test run, data for hypos is collected from RedCap surveys and for RCT data is collected from CGM downloads</description>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="36"/>
                <counts group_id="E3" events="27" subjects_affected="15" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Non serious adverse event</sub_title>
                <description>Nausea without vomiting</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Steven J. Russell</name_or_title>
      <organization>Mass. General Hospital</organization>
      <phone>617-726-8722</phone>
      <email>sjrussell@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

